Michael D. Allen

Array ( [id] => 16072347 [patent_doc_number] => 20200190160 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-18 [patent_title] => PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS [patent_app_type] => utility [patent_app_number] => 16/799380 [patent_app_country] => US [patent_app_date] => 2020-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38106 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16799380 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16012781 [patent_doc_number] => 20200181233 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIAS AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 16/797778 [patent_app_country] => US [patent_app_date] => 2020-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39283 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16797778 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16108651 [patent_doc_number] => 20200206348 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB [patent_app_type] => utility [patent_app_number] => 16/796163 [patent_app_country] => US [patent_app_date] => 2020-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41464 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16796163 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16090413 [patent_doc_number] => 20200199193 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIAS AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 16/793721 [patent_app_country] => US [patent_app_date] => 2020-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39314 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16793721 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16090415 [patent_doc_number] => 20200199194 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS [patent_app_type] => utility [patent_app_number] => 16/794035 [patent_app_country] => US [patent_app_date] => 2020-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37573 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16794035 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16016071 [patent_doc_number] => 20200182878 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => USE OF HE4 AND OTHER BIOCHEMICAL MARKERS FOR ASSESSMENT OF OVARIAN CANCERS [patent_app_type] => utility [patent_app_number] => 16/788442 [patent_app_country] => US [patent_app_date] => 2020-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10632 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16788442 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15963201 [patent_doc_number] => 20200165352 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => VARIANTS OF CD38 ANTIBODY AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/786563 [patent_app_country] => US [patent_app_date] => 2020-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38835 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16786563 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16111587 [patent_doc_number] => 20200207816 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => ENHANCING ANTI-CANCER ACTIVITY OF IMMUNOMODULATORY FC FUSION PROTEINS [patent_app_type] => utility [patent_app_number] => 16/737745 [patent_app_country] => US [patent_app_date] => 2020-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31587 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16737745 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17460315 [patent_doc_number] => 20220073620 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => ANTIBODY FUSION PROTEIN, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/418838 [patent_app_country] => US [patent_app_date] => 2019-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8411 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17418838 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18427657 [patent_doc_number] => 11672858 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-13 [patent_title] => Bispecific antibody molecules binding to CD3 and TYRP-1 [patent_app_type] => utility [patent_app_number] => 16/721254 [patent_app_country] => US [patent_app_date] => 2019-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 114 [patent_no_of_words] => 57940 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 263 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16721254 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16326879 [patent_doc_number] => 20200297844 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => Antibodies to TIGIT [patent_app_type] => utility [patent_app_number] => 16/703770 [patent_app_country] => US [patent_app_date] => 2019-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26139 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16703770 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17343688 [patent_doc_number] => 20220010019 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => Targeting intraepithelial lymphocytes for treatment of metabolic syndrome [patent_app_type] => utility [patent_app_number] => 17/297153 [patent_app_country] => US [patent_app_date] => 2019-11-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12112 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17297153 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17274487 [patent_doc_number] => 20210380685 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => Methods of Treating Rheumatoid Arthritis [patent_app_type] => utility [patent_app_number] => 17/283690 [patent_app_country] => US [patent_app_date] => 2019-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30297 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17283690 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18368161 [patent_doc_number] => 11648309 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-16 [patent_title] => Anti-netrin-1 antibody [patent_app_type] => utility [patent_app_number] => 16/657200 [patent_app_country] => US [patent_app_date] => 2019-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 9 [patent_no_of_words] => 11891 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16657200 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15616107 [patent_doc_number] => 20200078458 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-12 [patent_title] => Cancer-Cell-Specific Antibody, Anticancer Drug, and Cancer Testing Method [patent_app_type] => utility [patent_app_number] => 16/578861 [patent_app_country] => US [patent_app_date] => 2019-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21837 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16578861 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15678513 [patent_doc_number] => 20200093920 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => COMPOSITIONS, KITS, AND METHODS FOR THE DIAGNOSIS, PROGNOSIS, MONITORING, TREATMENT AND MODULATION OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AND HYPOXIA ASSOCIATED ANGIOGENESIS DISORDERS USING GALECTIN-1 [patent_app_type] => utility [patent_app_number] => 16/573374 [patent_app_country] => US [patent_app_date] => 2019-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64645 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16573374 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15589741 [patent_doc_number] => 20200071405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => ANTIBODY CONSTRUCTS FOR CDH19 AND CD3 [patent_app_type] => utility [patent_app_number] => 16/570129 [patent_app_country] => US [patent_app_date] => 2019-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57623 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16570129 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17157267 [patent_doc_number] => 20210318318 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => Kinase Activity In Tumors [patent_app_type] => utility [patent_app_number] => 17/271712 [patent_app_country] => US [patent_app_date] => 2019-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26613 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17271712 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17168838 [patent_doc_number] => 20210322508 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => PEPTIDES AND COMPOSITIONS FOR TARGETED TREATMENT AND IMAGING [patent_app_type] => utility [patent_app_number] => 17/268046 [patent_app_country] => US [patent_app_date] => 2019-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 158609 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -54 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17268046 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15363671 [patent_doc_number] => 20200017600 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-16 [patent_title] => VARIANTS OF CD38 ANTIBODY AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/512206 [patent_app_country] => US [patent_app_date] => 2019-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38832 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16512206 [rel_patent_id] =>[rel_patent_doc_number] =>)